SCHEMBL4674607

SCHEMBL4674607

O=C(C=C(O)c1nn[nH]n1)c1ccn(Cc2ccccc2)n1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HDAC1 Q13547 3/20 0.42
CES1 P23141 1/20 0.41
NCEH1 Q6PIU2 1/20 0.41
CACNA1G O43497 6/20 0.39
CACNA1I Q9P0X4 6/20 0.39
ITK Q08881 1/20 0.38
CACNA1H O95180 5/20 0.36
NPC1 O15118 4/20 0.36
RAB9A P51151 4/20 0.36
HDAC3 O15379 1/20 0.36
HDAC4 P56524 1/20 0.36
HDAC7 Q8WUI4 1/20 0.36
HDAC2 Q92769 1/20 0.36
HDAC10 Q969S8 1/20 0.36
HDAC11 Q96DB2 1/20 0.36
HDAC8 Q9BY41 1/20 0.36
HDAC6 Q9UBN7 1/20 0.36
HDAC9 Q9UKV0 1/20 0.36
HDAC5 Q9UQL6 1/20 0.36
ALDH1A1 P00352 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4674961 0.91 LMNA (0.34) HDAC1CES1NCEH1CACNA1GCACNA1I
SCHEMBL4672837 0.90 CACNA1G (0.40) HDAC1CACNA1GCACNA1ICACNA1HNPC1
SCHEMBL4673527 0.90 HDAC1 (0.34) HDAC1CES1NCEH1CACNA1GCACNA1I
SCHEMBL4675309 0.90 NPC1 (0.39) HDAC1CES1NCEH1CACNA1GCACNA1I
SCHEMBL4677812 0.89 L3MBTL1 (0.44) HDAC1CES1NCEH1NPC1RAB9A
SCHEMBL4671941 0.88 LMNA (0.38) HDAC1CES1NCEH1CACNA1GCACNA1I
SCHEMBL4678301 0.87 CACNA1G (0.43) HDAC1CACNA1GCACNA1ICACNA1HNPC1
SCHEMBL4670920 0.86 ALDH1A1 (0.42) HDAC1CES1NCEH1NPC1RAB9A
SCHEMBL4676739 0.86 HDAC1 (0.34) HDAC1CES1NCEH1HDAC3HDAC4
SCHEMBL4679047 0.82 HDAC1 (0.45) HDAC1CACNA1GCACNA1IITKCACNA1H

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1142872-B1 AROMATIC HETEROCYCLE COMPOUNDS HAVING HIV INTEGRASE INHIBITING ACTIVITIES SHIONOGI & CO (JP) 2008-10-15 EP disclosed
US-7098201-B2 Heteroaromatic derivatives having an inhibitory activity against HIV integrase SHIONOGI & CO., LTD. (JP) 2006-08-29 US disclosed
US-20040002485-A1 Heteroaromatic derivatives having an inhibitory activity against HIV integrase FUJISHITA TOSHIO (JP) 2004-01-01 US disclosed
US-6645956-B1 1-(5-(4-fluorobenzyl)furan-2-yl)-3-hydroxy-3-(1H-1,2,4-triazol-3 -yl)-propenone; viricides; AIDS treatment SHIONOGI & CO., LTD. (JP) 2003-11-11 US disclosed
US-6620841-B1 Furan or benzofuran derivatives substituted with triazole; acquired immunodeficiency syndrome (AIDS) SHIONOGI & CO., LTD. (JP) 2003-09-16 US disclosed
CN-1335834-A Aromatic heterocyclic compounds having HIV integrase inhibitory activity SHIONOGI & CO (JP) 2002-02-13 CN disclosed
EP-1142872-A1 AROMATIC HETEROCYCLE COMPOUNDS HAVING HIV INTEGRASE INHIBITING ACTIVITIES SHIONOGI & CO., LTD. (JP) 2001-10-10 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040002485-A1 Heteroaromatic derivatives having an inhibitory activity against HIV integrase RCOR1, BCOR, CYP8B1 HDAC1 250/4885CES1 445/4885NCEH1 1046/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.